These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18173819)

  • 1. Assessing the relative efficacy of different agents based on the outcomes from meta-analyses.
    Boonen S; Vanderschueren D; Haentjens P
    Int J Clin Pract; 2008 Jan; 62(1):164-5; author reply 165-6. PubMed ID: 18173819
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML
    Curr Med Res Opin; 2010 Nov; 26(11):2553-63. PubMed ID: 20858031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL; Wan SL
    Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness of anti-resorption therapies of postmenopausal osteoporosis].
    Stĕpán J
    Vnitr Lek; 2007 Mar; 53(3):293-9. PubMed ID: 17503641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract]   [Full Text] [Related]  

  • 11. [Which treatment for osteoporosis in women with contraindication to HRT?].
    Trémollieres F
    Rev Prat; 2010 Oct; 60(8):1133-6. PubMed ID: 21197752
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteoporosis treatment options expand.
    Mayo Clin Health Lett; 2010 Nov; 28(11):4. PubMed ID: 21158019
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
    von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
    Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ethics of placebo in studies with fracture end points in osteoporosis.
    Stein CM; Ray WA
    N Engl J Med; 2010 Sep; 363(14):1367-70; discussion e21. PubMed ID: 20879888
    [No Abstract]   [Full Text] [Related]  

  • 16. Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
    Bone HG; Santora AC; Chattopadhyay A; Liberman U
    J Bone Miner Res; 2005 Nov; 20(11):2064-5. PubMed ID: 16234982
    [No Abstract]   [Full Text] [Related]  

  • 17. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 18. Bisphosphonates for osteoporosis.
    Favus MJ
    N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugs for postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2011 Nov; 9(111):67-74. PubMed ID: 22033166
    [No Abstract]   [Full Text] [Related]  

  • 20. Denosumab, osteoporosis, and prevention of fractures.
    Blythe SL
    N Engl J Med; 2009 Nov; 361(22):2189-90; author reply 2190-1. PubMed ID: 19950410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.